Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Dan Theodorescu

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-SRG
Phone303/724-3152

    Collapse Research 
    Collapse research activities and funding
    P30CA046934     (THEODORESCU, DAN)Mar 1, 1988 - Jan 31, 2022
    NIH/NCI
    University of Colorado Cancer Center Support Grant
    Role: Principal Investigator

    R29CA075115     (THEODORESCU, DAN)Sep 1, 1997 - Aug 31, 2002
    NIH/NCI
    MECHANISMS OF BLADDER CANCER INVANSION
    Role: Principal Investigator

    R01CA075115     (THEODORESCU, DAN)Sep 1, 1997 - Mar 31, 2020
    NIH/NCI
    Regulation and Targeting of CD24 in Bladder Cancer
    Role: Principal Investigator

    R01CA085329     (THEODORESCU, DAN)Mar 1, 2001 - Feb 28, 2006
    NIH/NCI
    ENDOTHELIAL GROWTH FACTOR IN PROSTATE CANCER METASTASIS
    Role: Principal Investigator

    P01CA104106     (PASCHAL, BRYCE)Feb 1, 2004 - Aug 31, 2016
    NIH/NCI
    Signaling and Progression in Prostate Cancer
    Role: Co-Principal Investigator

    R01CA143971     (THEODORESCU, DAN)Sep 24, 2010 - Jul 31, 2021
    NIH/NCI
    Understanding the AGL metastasis suppressor for therapeutic gain
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Ngo AT, Thierheimer ML, Babur Ö, Rocheleau AD, Huang T, Pang J, Rigg RA, Mitrugno A, Theodorescu D, Burchard J, Nan X, Demir E, McCarty OJ, Aslan JE. Assessment of roles for the Rho-specific guanine nucleotide dissociation inhibitor Ly-GDI in platelet function: a spatial systems approach. Am J Physiol Cell Physiol. 2017 Apr 01; 312(4):C527-C536. PMID: 28148498.
      View in: PubMed
    2. Sottnik JL, Theodorescu D. CD44: A metastasis driver and therapeutic target. Oncoscience. 2016; 3(11-12):320-321. PMID: 28105456.
      View in: PubMed
    3. Earl J, Rico D, Carrillo-de-Santa-Pau E, Rodríguez-Santiago B, Méndez-Pertuz M, Auer H, Gómez G, Grossman HB, Pisano DG, Schulz WA, Pérez-Jurado LA, Carrato A, Theodorescu D, Chanock S, Valencia A, Real FX. Erratum to: The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies. BMC Genomics. 2016 Oct 25; 17(1):829. PMID: 27782819.
      View in: PubMed
    4. Yan C, Theodorescu D, Miller B, Kumar A, Kumar V, Ross D, Wempe MF. Synthesis of novel Ral inhibitors: An in vitro and in vivo study. Bioorg Med Chem Lett. 2016 Dec 01; 26(23):5815-5818. PMID: 27825764.
      View in: PubMed
    5. Oldenburg D, Ru Y, Weinhaus B, Cash S, Theodorescu D, Guin S. CD44 and RHAMM are essential for rapid growth of bladder cancer driven by loss of Glycogen Debranching Enzyme (AGL). BMC Cancer. 2016 Sep 05; 16:713. PMID: 27595989; PMCID: PMC5011830.
    6. Ahmed M, Sottnik JL, Dancik GM, Sahu D, Hansel DE, Theodorescu D, Schwartz MA. An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression. Cancer Cell. 2016 Sep 12; 30(3):432-43. PMID: 27593345.
      View in: PubMed
    7. Agarwal N, Dancik GM, Goodspeed A, Costello JC, Owens C, Duex JE, Theodorescu D. GON4L Drives Cancer Growth through a YY1-Androgen Receptor-CD24 Axis. Cancer Res. 2016 Sep 01; 76(17):5175-85. PMID: 27312530; PMCID: PMC5010501 [Available on 09/01/17].
    8. Nickerson ML, Witte N, Im KM, Turan S, Owens C, Misner K, Tsang SX, Cai Z, Wu S, Dean M, Costello JC, Theodorescu D. Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response. Oncogene. 2017 Jan 05; 36(1):35-46. PMID: 27270441.
      View in: PubMed
    9. Duberow DP, Brait M, Hoque MO, Theodorescu D, Sidransky D, Dasgupta S, Mathies RA. High-performance detection of somatic D-loop mutation in urothelial cell carcinoma patients by polymorphism ratio sequencing. J Mol Med (Berl). 2016 Sep; 94(9):1015-24. PMID: 27030170.
      View in: PubMed
    10. Frantzi M, van Kessel KE, Zwarthoff EC, Marquez M, Rava M, Malats N, Merseburger AS, Katafigiotis I, Stravodimos K, Mullen W, Zoidakis J, Makridakis M, Pejchinovski M, Critselis E, Lichtinghagen R, Brand K, Dakna M, Roubelakis MG, Theodorescu D, Vlahou A, Mischak H, Anagnou NP. Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study. Clin Cancer Res. 2016 Aug 15; 22(16):4077-86. PMID: 27026199.
      View in: PubMed
    11. Gustafson DL, Fowles JS, Brown KC, Theodorescu D. Drug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for Drug Repositioning in Cancer Therapy. Assay Drug Dev Technol. 2015 Dec; 13(10):623-7. PMID: 26690765; PMCID: PMC4692133 [Available on 12/01/16].
    12. Earl J, Rico D, Carrillo-de-Santa-Pau E, Rodríguez-Santiago B, Méndez-Pertuz M, Auer H, Gómez G, Grossman HB, Pisano DG, Schulz WA, Pérez-Jurado LA, Carrato A, Theodorescu D, Chanock S, Valencia A, Real FX. Erratum to: The UBC-40 Urothelial Bladder Cancer Cell Line Index: a genomic resource for functional studies. BMC Genomics. 2015 Nov 30; 16(1):1019. PMID: 26621286; PMCID: PMC4681452.
    13. Jones RT, Felsenstein KM, Theodorescu D. Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer. Urol Clin North Am. 2016 Feb; 43(1):77-86. PMID: 26614030; PMCID: PMC4663013 [Available on 02/01/17].
    14. Stern JL, Theodorescu D, Vogelstein B, Papadopoulos N, Cech TR. Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers. Genes Dev. 2015 Nov 01; 29(21):2219-24. PMID: 26515115; PMCID: PMC4647555.
    15. Guin S, Ru Y, Agarwal N, Lew CR, Owens C, Comi GP, Theodorescu D. Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis. Clin Cancer Res. 2016 Mar 01; 22(5):1274-83. PMID: 26490312; PMCID: PMC4775343 [Available on 03/01/17].
    16. Marie C, Verkerke HP, Theodorescu D, Petri WA. A whole-genome RNAi screen uncovers a novel role for human potassium channels in cell killing by the parasite Entamoeba histolytica. Sci Rep. 2015 Sep 08; 5:13613. PMID: 26346926; PMCID: PMC4561901.
    17. Hensel J, Duex JE, Owens C, Dancik GM, Edwards MG, Frierson HF, Theodorescu D. Patient Mutation Directed shRNA Screen Uncovers Novel Bladder Tumor Growth Suppressors. Mol Cancer Res. 2015 Sep; 13(9):1306-15. PMID: 26078295; PMCID: PMC4573363.
    18. Ritterson Lew C, Guin S, Theodorescu D. Targeting glycogen metabolism in bladder cancer. Nat Rev Urol. 2015 Jul; 12(7):383-91. PMID: 26032551; PMCID: PMC4678000.
    19. Earl J, Rico D, Carrillo-de-Santa-Pau E, Rodríguez-Santiago B, Méndez-Pertuz M, Auer H, Gómez G, Grossman HB, Pisano DG, Schulz WA, Pérez-Jurado LA, Carrato A, Theodorescu D, Chanock S, Valencia A, Real FX. The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies. BMC Genomics. 2015 May 22; 16:403. PMID: 25997541; PMCID: PMC4470036.
    20. Zhao D, Besser AH, Wander SA, Sun J, Zhou W, Wang B, Ince T, Durante MA, Guo W, Mills G, Theodorescu D, Slingerland J. Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation. Oncogene. 2015 Oct; 34(43):5447-59. PMID: 25684140; PMCID: PMC4537852.
    21. Venkatasubramanian S, Dhiman R, Paidipally P, Cheekatla SS, Tripathi D, Welch E, Tvinnereim AR, Jones B, Theodorescu D, Barnes PF, Vankayalapati R. A rho GDP dissociation inhibitor produced by apoptotic T-cells inhibits growth of Mycobacterium tuberculosis. PLoS Pathog. 2015 Feb; 11(2):e1004617. PMID: 25659138; PMCID: PMC4450061.
    22. Borah S, Xi L, Zaug AJ, Powell NM, Dancik GM, Cohen SB, Costello JC, Theodorescu D, Cech TR. Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science. 2015 Feb 27; 347(6225):1006-10. PMID: 25722414; PMCID: PMC4640672.
    23. Guin S, Theodorescu D. The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer. Acta Pharmacol Sin. 2015 Mar; 36(3):291-7. PMID: 25557115; PMCID: PMC4349922.
    24. Apolo AB, Vogelzang NJ, Theodorescu D. New and promising strategies in the management of bladder cancer. Am Soc Clin Oncol Educ Book. 2015; 105-12. PMID: 25993148.
      View in: PubMed
    25. Yan C, Theodorescu D. One step closer to targeting RAS. Cell Cycle. 2015; 14(3):287-8. PMID: 25591050; PMCID: PMC4614980.
    26. Yan C, Jones DN, Theodorescu D. Drugging the Ral GTPase. Small GTPases. 2015; 6(3):157-9. PMID: 26280620; PMCID: PMC4601353.
    27. Griner EM, Dancik GM, Costello JC, Owens C, Guin S, Edwards MG, Brautigan DL, Theodorescu D. RhoC Is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer. Mol Cancer Res. 2015 Mar; 13(3):483-92. PMID: 25516960; PMCID: PMC4369172.
    28. Albersen M, Cartwright R, Choyke P, Goldenberg SL, Goldman H, Lawrentschuk N, Linehan WM, Murphy D, Nagler H, Scardino P, Shortliffe L, Stenzl A, Theodorescu D. Looking forward, looking back-10 years in urology. Nat Rev Urol. 2014 11; 11(11):649-55. PMID: 25348169.
      View in: PubMed
    29. Dinney CP, Hansel D, McConkey D, Shipley W, Hagan M, Dreicer R, Lerner S, Czerniak B, Waldman F, Groshen S, True LD, Petricoin E, Theodorescu D, Hruszkewycz A, Bajorin D. Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. Urol Oncol. 2014 Nov; 32(8):1108-15. PMID: 25443274; PMCID: PMC4262150.
    30. Ostenfeld MS, Jeppesen DK, Laurberg JR, Boysen AT, Bramsen JB, Primdal-Bengtson B, Hendrix A, Lamy P, Dagnaes-Hansen F, Rasmussen MH, Bui KH, Fristrup N, Christensen EI, Nordentoft I, Morth JP, Jensen JB, Pedersen JS, Beck M, Theodorescu D, Borre M, Howard KA, Dyrskjøt L, Ørntoft TF. Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties. Cancer Res. 2014 Oct 15; 74(20):5758-71. PMID: 25261234.
      View in: PubMed
    31. Nickerson ML, Dancik GM, Im KM, Edwards MG, Turan S, Brown J, Ruiz-Rodriguez C, Owens C, Costello JC, Guo G, Tsang SX, Li Y, Zhou Q, Cai Z, Moore LE, Lucia MS, Dean M, Theodorescu D. Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer. Clin Cancer Res. 2014 Sep 15; 20(18):4935-48. PMID: 25225064; PMCID: PMC4166537.
    32. Yan C, Liu D, Li L, Wempe MF, Guin S, Khanna M, Meier J, Hoffman B, Owens C, Wysoczynski CL, Nitz MD, Knabe WE, Ahmed M, Brautigan DL, Paschal BM, Schwartz MA, Jones DN, Ross D, Meroueh SO, Theodorescu D. Discovery and characterization of small molecules that target the GTPase Ral. Nature. 2014 Nov 20; 515(7527):443-7. PMID: 25219851; PMCID: PMC4351747.
    33. Costello JC, Theodorescu D. Decade in review-bladder cancer: international progress: from cytology to genomics. Nat Rev Urol. 2014 11; 11(11):609-10. PMID: 25179501.
      View in: PubMed
    34. Apolo AB, Hoffman V, Kaag MG, Latini DM, Lee CT, Rosenberg JE, Knowles M, Theodorescu D, Czerniak BA, Efstathiou JA, Albert ML, Sridhar SS, Margulis V, Matin SF, Galsky MD, Hansel D, Kamat AM, Flaig TW, Smith AB, Messing E, Zipursky Quale D, Lotan Y. Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. Urol Oncol. 2015 Feb; 33(2):53-64. PMID: 25065704.
      View in: PubMed
    35. Ru Y, Kechris KJ, Tabakoff B, Hoffman P, Radcliffe RA, Bowler R, Mahaffey S, Rossi S, Calin GA, Bemis L, Theodorescu D. The multiMiR R package and database: integration of microRNA-target interactions along with their disease and drug associations. Nucleic Acids Res. 2014; 42(17):e133. PMID: 25063298; PMCID: PMC4176155.
    36. Hussain M, Theodorescu D. Bladder cancer: bladder preservation--learning what we don't know. Nat Rev Urol. 2014 Jun; 11(6):310-2. PMID: 24841166.
      View in: PubMed
    37. Guin S, Pollard C, Ru Y, Ritterson Lew C, Duex JE, Dancik G, Owens C, Spencer A, Knight S, Holemon H, Gupta S, Hansel D, Hellerstein M, Lorkiewicz P, Lane AN, Fan TW, Theodorescu D. Role in tumor growth of a glycogen debranching enzyme lost in glycogen storage disease. J Natl Cancer Inst. 2014 Apr 03; 106(5). PMID: 24700805; PMCID: PMC4580555.
    38. Dancik GM, Owens CR, Iczkowski KA, Theodorescu D. A cell of origin gene signature indicates human bladder cancer has distinct cellular progenitors. Stem Cells. 2014 Apr; 32(4):974-82. PMID: 24357085; PMCID: PMC3960367.
    39. Kaur S, Momi N, Chakraborty S, Wagner DG, Horn AJ, Lele SM, Theodorescu D, Batra SK. Altered expression of transmembrane mucins, MUC1 and MUC4, in bladder cancer: pathological implications in diagnosis. PLoS One. 2014; 9(3):e92742. PMID: 24671186; PMCID: PMC3966814.
    40. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014 Feb 19; 6(224):224ra24. PMID: 24553385; PMCID: PMC4017867.
    41. Kim Y, Guntupalli SR, Lee SJ, Behbakht K, Theodorescu D, Lee JK, Diamond JR. Retrospective analysis of survival improvement by molecular biomarker-based personalized chemotherapy for recurrent ovarian cancer. PLoS One. 2014; 9(2):e86532. PMID: 24505259; PMCID: PMC3914805.
    42. Hussain M, Theodorescu D. Words of wisdom. Re: Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. Eur Urol. 2014 Feb; 65(2):501. PMID: 24407210.
      View in: PubMed
    43. Dancik GM, Theodorescu D. Robust prognostic gene expression signatures in bladder cancer and lung adenocarcinoma depend on cell cycle related genes. PLoS One. 2014; 9(1):e85249. PMID: 24465512; PMCID: PMC3898982.
    44. Dancik GM, Theodorescu D. Pharmacogenomics in bladder cancer. Urol Oncol. 2014 Jan; 32(1):16-22. PMID: 24360659; PMCID: PMC3904434.
    45. Frantzi M, Metzger J, Banks RE, Husi H, Klein J, Dakna M, Mullen W, Cartledge JJ, Schanstra JP, Brand K, Kuczyk MA, Mischak H, Vlahou A, Theodorescu D, Merseburger AS. Discovery and validation of urinary biomarkers for detection of renal cell carcinoma. J Proteomics. 2014 Feb 26; 98:44-58. PMID: 24374379.
      View in: PubMed
    46. Guin S, Ru Y, Wynes MW, Mishra R, Lu X, Owens C, Barn AE, Vasu VT, Hirsch FR, Kern JA, Theodorescu D. Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression. J Thorac Oncol. 2013 Dec; 8(12):1492-501. PMID: 24389431; PMCID: PMC3934792.
    47. Theodorescu D, Cech TR. Telomerase in bladder cancer: back to a better future? Eur Urol. 2014 Feb; 65(2):370-1. PMID: 24184027.
      View in: PubMed
    48. Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahloun AG, Ozawa T, Gerard J, Zhuang D, Zhang S, Navai N, Siefker-Radtke A, Phillips JJ, Robinson BD, Rubin MA, Volkmer B, Hautmann R, Küfer R, Hogendoorn PC, Netto G, Theodorescu D, James CD, Czerniak B, Miettinen M, Waldman T. Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet. 2013 Dec; 45(12):1428-30. PMID: 24121789; PMCID: PMC3875130.
    49. Guo G, Sun X, Chen C, Wu S, Huang P, Li Z, Dean M, Huang Y, Jia W, Zhou Q, Tang A, Yang Z, Li X, Song P, Zhao X, Ye R, Zhang S, Lin Z, Qi M, Wan S, Xie L, Fan F, Nickerson ML, Zou X, Hu X, Xing L, Lv Z, Mei H, Gao S, Liang C, Gao Z, Lu J, Yu Y, Liu C, Li L, Fang X, Jiang Z, Yang J, Li C, Zhao X, Chen J, Zhang F, Lai Y, Lin Z, Zhou F, Chen H, Chan HC, Tsang S, Theodorescu D, Li Y, Zhang X, Wang J, Yang H, Gui Y, Wang J, Cai Z. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet. 2013 Dec; 45(12):1459-63. PMID: 24121792.
      View in: PubMed
    50. Wang H, Ru Y, Sanchez-Carbayo M, Wang X, Kieft JS, Theodorescu D. Translation initiation factor eIF3b expression in human cancer and its role in tumor growth and lung colonization. Clin Cancer Res. 2013 Jun 01; 19(11):2850-60. PMID: 23575475; PMCID: PMC3695228.
    51. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih IeM, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013 Apr 09; 110(15):6021-6. PMID: 23530248; PMCID: PMC3625331.
    52. Said N, Frierson HF, Sanchez-Carbayo M, Brekken RA, Theodorescu D. Loss of SPARC in bladder cancer enhances carcinogenesis and progression. J Clin Invest. 2013 Feb; 123(2):751-66. PMID: 23321672; PMCID: PMC3561835.
    53. Grau L, Luque-Garcia JL, González-Peramato P, Theodorescu D, Palou J, Fernandez-Gomez JM, Sánchez-Carbayo M. A quantitative proteomic analysis uncovers the relevance of CUL3 in bladder cancer aggressiveness. PLoS One. 2013; 8(1):e53328. PMID: 23308193; PMCID: PMC3540081.
    54. Griner EM, Theodorescu D. The faces and friends of RhoGDI2. Cancer Metastasis Rev. 2012 Dec; 31(3-4):519-28. PMID: 22718398.
      View in: PubMed
    55. Hensel JA, Flaig TW, Theodorescu D. Clinical opportunities and challenges in targeting tumour dormancy. Nat Rev Clin Oncol. 2013 Jan; 10(1):41-51. PMID: 23183631.
      View in: PubMed
    56. Said N, Theodorescu D. RhoGDI2 suppresses bladder cancer metastasis via reduction of inflammation in the tumor microenvironment. Oncoimmunology. 2012 Oct 01; 1(7):1175-1177. PMID: 23170270.
      View in: PubMed
    57. Overdevest JB, Knubel KH, Duex JE, Thomas S, Nitz MD, Harding MA, Smith SC, Frierson HF, Conaway M, Theodorescu D. CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated. Proc Natl Acad Sci U S A. 2012 Dec 18; 109(51):E3588-96. PMID: 23012401; PMCID: PMC3529071.
    58. Nordentoft I, Birkenkamp-Demtroder K, Agerbæk M, Theodorescu D, Ostenfeld MS, Hartmann A, Borre M, Ørntoft TF, Dyrskjøt L. miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics. 2012 Sep 06; 5:40. PMID: 22954303; PMCID: PMC3473298.
    59. Thomas S, Harding MA, Smith SC, Overdevest JB, Nitz MD, Frierson HF, Tomlins SA, Kristiansen G, Theodorescu D. CD24 is an effector of HIF-1-driven primary tumor growth and metastasis. Cancer Res. 2012 Nov 01; 72(21):5600-12. PMID: 22926560; PMCID: PMC3488144.
    60. Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ, Milowsky MI, Theodorescu D, Vaughn DJ, Galsky MD, Soloway MS, Quinn DI. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol. 2013 Jan; 63(1):58-66. PMID: 22917984.
      View in: PubMed
    61. Kohan DE, Cleland JG, Rubin LJ, Theodorescu D, Barton M. Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? Life Sci. 2012 Oct 15; 91(13-14):528-39. PMID: 22967485.
      View in: PubMed
    62. Flaig TW, Theodorescu D. Words of wisdom. Re: Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. Eur Urol. 2012 Jul; 62(1):183-4. PMID: 22640860; PMCID: PMC4024709.
    63. Smith SC, Baras AS, Owens CR, Dancik G, Theodorescu D. Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer. Cancer Res. 2012 Jul 15; 72(14):3480-91. PMID: 22586063; PMCID: PMC3842017.
    64. DeGraff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, Smolkin ME, Chang SS, Cookson MS, Herrick MK, Shariat SF, Steinberg GD, Frierson HF, Wu XR, Theodorescu D, Matusik RJ. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PLoS One. 2012; 7(5):e36669. PMID: 22590586; PMCID: PMC3349679.
    65. Said N, Theodorescu D. Permissive role of endothelin receptors in tumor metastasis. Life Sci. 2012 Oct 15; 91(13-14):522-7. PMID: 22846215.
      View in: PubMed
    66. Griner EM, Churchill ME, Brautigan DL, Theodorescu D. PKCa phosphorylation of RhoGDI2 at Ser31 disrupts interactions with Rac1 and decreases GDI activity. Oncogene. 2013 Feb 21; 32(8):1010-7. PMID: 22469974; PMCID: PMC3578973.
    67. Said N, Sanchez-Carbayo M, Smith SC, Theodorescu D. RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. J Clin Invest. 2012 Apr; 122(4):1503-18. PMID: 22406535; PMCID: PMC3314474.
    68. Dancika GM, Theodorescu D. Perspectives on personalized cancer care. Urol Oncol. 2012 Mar-Apr; 30(2):121-5. PMID: 22489325.
      View in: PubMed
    69. Ferriss JS, Kim Y, Duska L, Birrer M, Levine DA, Moskaluk C, Theodorescu D, Lee JK. Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance. PLoS One. 2012; 7(2):e30550. PMID: 22348014; PMCID: PMC3277593.
    70. Flaig TW, Theodorescu D. Bladder cancer in 2011: the dawn of personalized medicine. Nat Rev Urol. 2011 Dec 20; 9(2):65-6. PMID: 22187014; PMCID: PMC4020619.
    71. Williams PD, Owens CR, Dziegielewski J, Moskaluk CA, Read PW, Larner JM, Story MD, Brock WA, Amundson SA, Lee JK, Theodorescu D. Cyclophilin B expression is associated with in vitro radioresistance and clinical outcome after radiotherapy. Neoplasia. 2011 Dec; 13(12):1122-31. PMID: 22241958; PMCID: PMC3257187.
    72. Cekic C, Sag D, Li Y, Theodorescu D, Strieter RM, Linden J. Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J Immunol. 2012 Jan 01; 188(1):198-205. PMID: 22116822; PMCID: PMC3819109.
    73. Dancik GM, Ru Y, Owens CR, Theodorescu D. A framework to select clinically relevant cancer cell lines for investigation by establishing their molecular similarity with primary human cancers. Cancer Res. 2011 Dec 15; 71(24):7398-409. PMID: 22012889; PMCID: PMC3242880.
    74. Ru Y, Dancik GM, Theodorescu D. Biomarkers for prognosis and treatment selection in advanced bladder cancer patients. Curr Opin Urol. 2011 Sep; 21(5):420-7. PMID: 21814055; PMCID: PMC3257805.
    75. Cheng F, Theodorescu D, Schulman IG, Lee JK. In vitro transcriptomic prediction of hepatotoxicity for early drug discovery. J Theor Biol. 2011 Dec 07; 290:27-36. PMID: 21884709; PMCID: PMC3386613.
    76. Dancik G, Aisner D, Theodorescu D. A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors. PLoS Curr. 2011 Aug 11; 3:RRN1248. PMID: 21858252; PMCID: PMC3157080.
    77. Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, Wu R, Chen C, Li X, Zhou L, He M, Li Z, Sun X, Jia W, Chen J, Yang S, Zhou F, Zhao X, Wan S, Ye R, Liang C, Liu Z, Huang P, Liu C, Jiang H, Wang Y, Zheng H, Sun L, Liu X, Jiang Z, Feng D, Chen J, Wu S, Zou J, Zhang Z, Yang R, Zhao J, Xu C, Yin W, Guan Z, Ye J, Zhang H, Li J, Kristiansen K, Nickerson ML, Theodorescu D, Li Y, Zhang X, Li S, Wang J, Yang H, Wang J, Cai Z. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet. 2011 Aug 07; 43(9):875-8. PMID: 21822268.
      View in: PubMed
    78. Nitz MD, Harding MA, Smith SC, Thomas S, Theodorescu D. RREB1 transcription factor splice variants in urologic cancer. Am J Pathol. 2011 Jul; 179(1):477-86. PMID: 21703425; PMCID: PMC3123806.
    79. Aisner DL, Theodorescu D. Genetic testing for metastasis: potential for improved cancer treatment. Future Oncol. 2011 Jun; 7(6):697-701. PMID: 21675831.
      View in: PubMed
    80. Overdevest JB, Thomas S, Kristiansen G, Hansel DE, Smith SC, Theodorescu D. CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. Cancer Res. 2011 Jun 01; 71(11):3802-11. PMID: 21482678; PMCID: PMC4283788.
    81. Smith SC, Baras AS, Dancik G, Ru Y, Ding KF, Moskaluk CA, Fradet Y, Lehmann J, Stöckle M, Hartmann A, Lee JK, Theodorescu D. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol. 2011 Feb; 12(2):137-43. PMID: 21256081; PMCID: PMC3613042.
    82. Smith SC, Havaleshko DM, Moon K, Baras AS, Lee J, Bekiranov S, Burke DJ, Theodorescu D. Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents. Neoplasia. 2011 Jan; 13(1):72-80. PMID: 21253455; PMCID: PMC3023847.
    83. Said N, Smith S, Sanchez-Carbayo M, Theodorescu D. Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J Clin Invest. 2011 Jan; 121(1):132-47. PMID: 21183790; PMCID: PMC3007145.
    84. Thomas S, Overdevest JB, Nitz MD, Williams PD, Owens CR, Sanchez-Carbayo M, Frierson HF, Schwartz MA, Theodorescu D. Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer. Cancer Res. 2011 Feb 01; 71(3):832-41. PMID: 21148751; PMCID: PMC4306590.
    85. Wu Z, Owens C, Chandra N, Popovic K, Conaway M, Theodorescu D. RalBP1 is necessary for metastasis of human cancer cell lines. Neoplasia. 2010 Dec; 12(12):1003-12. PMID: 21170262; PMCID: PMC3003135.
    86. Maroni P, Theodorescu D. Words of wisdom. Re: mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Eur Urol. 2010 Dec; 58(6):938-9. PMID: 21414863.
      View in: PubMed
    87. Jerde TJ, Wu Z, Theodorescu D, Bushman W. Regulation of phosphatase homologue of tensin protein expression by bone morphogenetic proteins in prostate epithelial cells. Prostate. 2011 Jun 01; 71(8):791-800. PMID: 21456062; PMCID: PMC3043153.
    88. Krupski TL, Stukenborg GJ, Moon K, Theodorescu D. The relationship of palliative transurethral resection of the prostate with disease progression in patients with prostate cancer. BJU Int. 2010 Nov; 106(10):1477-83. PMID: 20977594; PMCID: PMC4507368.
    89. Wang H, Owens C, Chandra N, Conaway MR, Brautigan DL, Theodorescu D. Phosphorylation of RalB is important for bladder cancer cell growth and metastasis. Cancer Res. 2010 Nov 01; 70(21):8760-9. PMID: 20940393; PMCID: PMC3025490.
    90. Mischak H, Allmaier G, Apweiler R, Attwood T, Baumann M, Benigni A, Bennett SE, Bischoff R, Bongcam-Rudloff E, Capasso G, Coon JJ, D'Haese P, Dominiczak AF, Dakna M, Dihazi H, Ehrich JH, Fernandez-Llama P, Fliser D, Frokiaer J, Garin J, Girolami M, Hancock WS, Haubitz M, Hochstrasser D, Holman RR, Ioannidis JP, Jankowski J, Julian BA, Klein JB, Kolch W, Luider T, Massy Z, Mattes WB, Molina F, Monsarrat B, Novak J, Peter K, Rossing P, Sánchez-Carbayo M, Schanstra JP, Semmes OJ, Spasovski G, Theodorescu D, Thongboonkerd V, Vanholder R, Veenstra TD, Weissinger E, Yamamoto T, Vlahou A. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med. 2010 Aug 25; 2(46):46ps42. PMID: 20739680.
      View in: PubMed
    91. Wilson SS, Theodorescu D. Rare bladder tumors: caveat emptor. Oncology (Williston Park). 2010 Aug; 24(9):838. PMID: 20923039.
      View in: PubMed
    92. Good DM, Zürbig P, Argilés A, Bauer HW, Behrens G, Coon JJ, Dakna M, Decramer S, Delles C, Dominiczak AF, Ehrich JH, Eitner F, Fliser D, Frommberger M, Ganser A, Girolami MA, Golovko I, Gwinner W, Haubitz M, Herget-Rosenthal S, Jankowski J, Jahn H, Jerums G, Julian BA, Kellmann M, Kliem V, Kolch W, Krolewski AS, Luppi M, Massy Z, Melter M, Neusüss C, Novak J, Peter K, Rossing K, Rupprecht H, Schanstra JP, Schiffer E, Stolzenburg JU, Tarnow L, Theodorescu D, Thongboonkerd V, Vanholder R, Weissinger EM, Mischak H, Schmitt-Kopplin P. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics. 2010 Nov; 9(11):2424-37. PMID: 20616184; PMCID: PMC2984241.
    93. Hansel DE, Platt E, Orloff M, Harwalker J, Sethu S, Hicks JL, De Marzo A, Steinle RE, Hsi ED, Theodorescu D, Ching CB, Eng C. Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol. 2010 Jun; 176(6):3062-72. PMID: 20395440; PMCID: PMC2877865.
    94. Harding MA, Theodorescu D. RhoGDI signaling provides targets for cancer therapy. Eur J Cancer. 2010 May; 46(7):1252-9. PMID: 20347589.
      View in: PubMed
    95. Pollard C, Smith SC, Theodorescu D. Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC). Expert Rev Mol Med. 2010 Mar 25; 12:e10. PMID: 20334706; PMCID: PMC3025483.
    96. Smith SC, Baras AS, Lee JK, Theodorescu D. The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Res. 2010 Mar 01; 70(5):1753-8. PMID: 20160033; PMCID: PMC2831138.
    97. Lee JK, Coutant C, Kim YC, Qi Y, Theodorescu D, Symmans WF, Baggerly K, Rouzier R, Pusztai L. Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2010 Jan 15; 16(2):711-8. PMID: 20068086; PMCID: PMC2807997.
    98. Ehdaie B, Smith SC, Theodorescu D. Personalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat. Can Urol Assoc J. 2009 Dec; 3(6 Suppl 4):S232-6. PMID: 20019992; PMCID: PMC2792449.
    99. Said N, Theodorescu D. Pathways of metastasis suppression in bladder cancer. Cancer Metastasis Rev. 2009 Dec; 28(3-4):327-33. PMID: 20013033.
      View in: PubMed
    100. Havaleshko DM, Smith SC, Cho H, Cheon S, Owens CR, Lee JK, Liotta LA, Espina V, Wulfkuhle JD, Petricoin EF, Theodorescu D. Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer. Neoplasia. 2009 Nov; 11(11):1185-93. PMID: 19881954; PMCID: PMC2767220.
    101. Hussain MH, Wood DP, Bajorin DF, Bochner BH, Dreicer R, Lamm DL, O'Donnell MA, Siefker-Radtke AO, Theodorescu D, Dinney CP. Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol. 2009 Dec 01; 27(34):5680-4. PMID: 19858384.
      View in: PubMed
    102. Williams PD, Cheon S, Havaleshko DM, Jeong H, Cheng F, Theodorescu D, Lee JK. Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res. 2009 Nov 01; 69(21):8302-9. PMID: 19843853; PMCID: PMC2784269.
    103. Pollard C, Nitz M, Baras A, Williams P, Moskaluk C, Theodorescu D. Genoproteomic mining of urothelial cancer suggests {gamma}-glutamyl hydrolase and diazepam-binding inhibitor as putative urinary markers of outcome after chemotherapy. Am J Pathol. 2009 Nov; 175(5):1824-30. PMID: 19815704; PMCID: PMC2774049.
    104. Cathro HP, Smolkin ME, Theodorescu D, Jo VY, Ferrone S, Frierson HF. Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas. Cancer Immunol Immunother. 2010 Mar; 59(3):465-72. PMID: 19756593; PMCID: PMC3426234.
    105. Ehdaie B, Stukenborg GJ, Theodorescu D. Renal transplant recipients and patients with end stage renal disease present with more advanced bladder cancer. J Urol. 2009 Oct; 182(4):1482-7. PMID: 19683766.
      View in: PubMed
    106. Slack-Davis JK, Hershey ED, Theodorescu D, Frierson HF, Parsons JT. Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model. Mol Cancer Ther. 2009 Aug; 8(8):2470-7. PMID: 19671741; PMCID: PMC2728172.
    107. Steeg PS, Anderson RL, Bar-Eli M, Chambers AF, Eccles SA, Hunter K, Itoh K, Kang Y, Matrisian LM, Sleeman JP, Theodorescu D, Thompson EW, Welch DR. An open letter to the FDA and other regulatory agencies: Preclinical drug development must consider the impact on metastasis. Clin Cancer Res. 2009 Jul 15; 15:4529. PMID: 25278743.
      View in: PubMed
    108. Schiffer E, Vlahou A, Petrolekas A, Stravodimos K, Tauber R, Geschwend JE, Neuhaus J, Stolzenburg JU, Conaway MR, Mischak H, Theodorescu D. Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin Cancer Res. 2009 Aug 01; 15(15):4935-43. PMID: 19602546.
      View in: PubMed
    109. Said N, Frierson HF, Chernauskas D, Conaway M, Motamed K, Theodorescu D. The role of SPARC in the TRAMP model of prostate carcinogenesis and progression. Oncogene. 2009 Oct 01; 28(39):3487-98. PMID: 19597474.
      View in: PubMed
    110. Haubitz M, Good DM, Woywodt A, Haller H, Rupprecht H, Theodorescu D, Dakna M, Coon JJ, Mischak H. Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis. Mol Cell Proteomics. 2009 Oct; 8(10):2296-307. PMID: 19564150; PMCID: PMC2758757.
    111. Wu Y, Moissoglu K, Wang H, Wang X, Frierson HF, Schwartz MA, Theodorescu D. Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function. Proc Natl Acad Sci U S A. 2009 Apr 07; 106(14):5807-12. PMID: 19321744; PMCID: PMC2667073.
    112. Moissoglu K, McRoberts KS, Meier JA, Theodorescu D, Schwartz MA. Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPases. Cancer Res. 2009 Apr 01; 69(7):2838-44. PMID: 19276387; PMCID: PMC2701105.
    113. Overdevest JB, Theodorescu D, Lee JK. Utilizing the molecular gateway: the path to personalized cancer management. Clin Chem. 2009 Apr; 55(4):684-97. PMID: 19246616; PMCID: PMC4529063.
    114. Smith SC, Theodorescu D. Learning therapeutic lessons from metastasis suppressor proteins. Nat Rev Cancer. 2009 Apr; 9(4):253-64. PMID: 19242414; PMCID: PMC2881216.
    115. Smith SC, Nicholson B, Nitz M, Frierson HF, Smolkin M, Hampton G, El-Rifai W, Theodorescu D. Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination. Am J Pathol. 2009 Feb; 174(2):371-9. PMID: 19147813; PMCID: PMC2630547.
    116. Dong L, Bard AJ, Richards WG, Nitz MD, Theodorescu D, Bueno R, Gordon GJ. A gene expression ratio-based diagnostic test for bladder cancer. Adv Appl Bioinform Chem. 2009; 2:17-22. PMID: 21918612; PMCID: PMC3169945.
    117. Smith SC, Theodorescu D. The Ral GTPase pathway in metastatic bladder cancer: key mediator and therapeutic target. Urol Oncol. 2009 Jan-Feb; 27(1):42-7. PMID: 19111797; PMCID: PMC3904428.
    118. Wu Z, Cho H, Hampton GM, Theodorescu D. Cdc6 and cyclin E2 are PTEN-regulated genes associated with human prostate cancer metastasis. Neoplasia. 2009 Jan; 11(1):66-76. PMID: 19107233; PMCID: PMC2606120.
    119. Williams PD, Lee JK, Theodorescu D. Genomancy: predicting tumour response to cancer therapy based on the oracle of genetics. Curr Oncol. 2009 Jan; 16(1):56-8. PMID: 19229372; PMCID: PMC2644622.
    120. Schwartz MA, McRoberts K, Coyner M, Andarawewa KL, Frierson HF, Sanders JM, Swenson S, Markland F, Conaway MR, Theodorescu D. Integrin agonists as adjuvants in chemotherapy for melanoma. Clin Cancer Res. 2008 Oct 01; 14(19):6193-7. PMID: 18829498.
      View in: PubMed
    121. Wu Y, Siadaty MS, Berens ME, Hampton GM, Theodorescu D. Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration. Oncogene. 2008 Nov 06; 27(52):6679-89. PMID: 18724390.
      View in: PubMed
    122. Williams PD, Lee JK, Theodorescu D. Molecular credentialing of rodent bladder carcinogenesis models. Neoplasia. 2008 Aug; 10(8):838-46. PMID: 18670642; PMCID: PMC2481571.
    123. Coon JJ, Zürbig P, Dakna M, Dominiczak AF, Decramer S, Fliser D, Frommberger M, Golovko I, Good DM, Herget-Rosenthal S, Jankowski J, Julian BA, Kellmann M, Kolch W, Massy Z, Novak J, Rossing K, Schanstra JP, Schiffer E, Theodorescu D, Vanholder R, Weissinger EM, Mischak H, Schmitt-Kopplin P. CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl. 2008 Jul 10; 2(7-8):964. PMID: 20130789.
      View in: PubMed
    124. Jones RA, Taylor AG, Bourguignon C, Steeves R, Fraser G, Lippert M, Theodorescu D, Mathews H, Kilbridge KL. Family interactions among African American prostate cancer survivors. Fam Community Health. 2008 Jul-Sep; 31(3):213-20. PMID: 18552602; PMCID: PMC2810541.
    125. Ehdaie B, Theodorescu D. Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis. Expert Rev Anticancer Ther. 2008 Jul; 8(7):1103-10. PMID: 18588455.
      View in: PubMed
    126. Wu Z, Gioeli D, Conaway M, Weber MJ, Theodorescu D. Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors. Prostate. 2008 Jun 15; 68(9):935-44. PMID: 18386291; PMCID: PMC2748221.
    127. Theodorescu D. Cryotherapy for prostate cancer: what we know, what we need to know. J Urol. 2008 Aug; 180(2):437-8. PMID: 18550127.
      View in: PubMed
    128. Smalley DM, Sheman NE, Nelson K, Theodorescu D. Isolation and identification of potential urinary microparticle biomarkers of bladder cancer. J Proteome Res. 2008 May; 7(5):2088-96. PMID: 18373357.
      View in: PubMed
    129. Theodorescu D, Schiffer E, Bauer HW, Douwes F, Eichhorn F, Polley R, Schmidt T, Schöfer W, Zürbig P, Good DM, Coon JJ, Mischak H. Discovery and validation of urinary biomarkers for prostate cancer. Proteomics Clin Appl. 2008 Mar 07; 2(4):556-570. PMID: 19759844.
      View in: PubMed
    130. Black PC, Brown GA, Inamoto T, Shrader M, Arora A, Siefker-Radtke AO, Adam L, Theodorescu D, Wu X, Munsell MF, Bar-Eli M, McConkey DJ, Dinney CP. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res. 2008 Mar 01; 14(5):1478-86. PMID: 18316572.
      View in: PubMed
    131. Steeg PS, Theodorescu D. Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol. 2008 Apr; 5(4):206-19. PMID: 18253104; PMCID: PMC2709494.
    132. Schiffer E, Mischak H, Theodorescu D, Vlahou A. Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform. World J Urol. 2008 Feb; 26(1):67-74. PMID: 18175124.
      View in: PubMed
    133. Nitz MD, Harding MA, Theodorescu D. Invasion and metastasis models for studying RhoGDI2 in bladder cancer. Methods Enzymol. 2008; 439:219-33. PMID: 18374168.
      View in: PubMed
    134. Ehdaie B, Theodorescu D. Molecular markers in transitional cell carcinoma of the bladder: New insights into mechanisms and prognosis. Indian J Urol. 2008 Jan; 24(1):61-7. PMID: 19468362; PMCID: PMC2684226.
    135. Bigler D, Gioeli D, Conaway MR, Weber MJ, Theodorescu D. Rap2 regulates androgen sensitivity in human prostate cancer cells. Prostate. 2007 Oct 01; 67(14):1590-9. PMID: 17918750.
      View in: PubMed
    136. Cho H, Smalley DM, Theodorescu D, Ley K, Lee JK. Statistical identification of differentially labeled peptides from liquid chromatography tandem mass spectrometry. Proteomics. 2007 Oct; 7(20):3681-92. PMID: 17879999.
      View in: PubMed
    137. Harding MA, Theodorescu D. RhoGDI2: a new metastasis suppressor gene: discovery and clinical translation. Urol Oncol. 2007 Sep-Oct; 25(5):401-6. PMID: 17826660.
      View in: PubMed
    138. Theodorescu D, Mischak H. Mass spectrometry based proteomics in urine biomarker discovery. World J Urol. 2007 Oct; 25(5):435-43. PMID: 17703310.
      View in: PubMed
    139. Herlevsen MC, Theodorescu D. Mass spectroscopic phosphoprotein mapping of Ral binding protein 1 (RalBP1/Rip1/RLIP76). Biochem Biophys Res Commun. 2007 Oct 12; 362(1):56-62. PMID: 17706599; PMCID: PMC2679903.
    140. Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, Karpovich J, Grimshaw A, Theodorescu D. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A. 2007 Aug 07; 104(32):13086-91. PMID: 17666531; PMCID: PMC1941805.
    141. Smith SC, Oxford G, Baras AS, Owens C, Havaleshko D, Brautigan DL, Safo MK, Theodorescu D. Expression of ral GTPases, their effectors, and activators in human bladder cancer. Clin Cancer Res. 2007 Jul 01; 13(13):3803-13. PMID: 17606711.
      View in: PubMed
    142. Herlevsen M, Oxford G, Owens CR, Conaway M, Theodorescu D. Depletion of major vault protein increases doxorubicin sensitivity and nuclear accumulation and disrupts its sequestration in lysosomes. Mol Cancer Ther. 2007 Jun; 6(6):1804-13. PMID: 17575109.
      View in: PubMed
    143. Oxford G, Smith SC, Hampton G, Theodorescu D. Expression profiling of Ral-depleted bladder cancer cells identifies RREB-1 as a novel transcriptional Ral effector. Oncogene. 2007 Nov 01; 26(50):7143-52. PMID: 17496927.
      View in: PubMed
    144. Flury SC, Galgano MT, Mills SE, Smolkin ME, Theodorescu D. Atypical small acinar proliferation: biopsy artefact or distinct pathological entity? BJU Int. 2007 Apr; 99(4):780-5. PMID: 17378841.
      View in: PubMed
    145. Wu Z, McRoberts KS, Theodorescu D. The role of PTEN in prostate cancer cell tropism to the bone micro-environment. Carcinogenesis. 2007 Jul; 28(7):1393-400. PMID: 17347137.
      View in: PubMed
    146. Jones RA, Taylor AG, Bourguignon C, Steeves R, Fraser G, Lippert M, Theodorescu D, Mathews H, Kilbridge KL. Complementary and alternative medicine modality use and beliefs among African American prostate cancer survivors. Oncol Nurs Forum. 2007 Mar; 34(2):359-64. PMID: 17573300; PMCID: PMC3616188.
    147. Ehdaie B, Theodorescu D. Organ-sparing techniques for penile cancer: quo vadis? Nat Clin Pract Urol. 2007 Apr; 4(4):182-3. PMID: 17310235.
      View in: PubMed
    148. Havaleshko DM, Cho H, Conaway M, Owens CR, Hampton G, Lee JK, Theodorescu D. Prediction of drug combination chemosensitivity in human bladder cancer. Mol Cancer Ther. 2007 Feb; 6(2):578-86. PMID: 17308055.
      View in: PubMed
    149. Mischak H, Apweiler R, Banks RE, Conaway M, Coon J, Dominiczak A, Ehrich JH, Fliser D, Girolami M, Hermjakob H, Hochstrasser D, Jankowski J, Julian BA, Kolch W, Massy ZA, Neusuess C, Novak J, Peter K, Rossing K, Schanstra J, Semmes OJ, Theodorescu D, Thongboonkerd V, Weissinger EM, Van Eyk JE, Yamamoto T. Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl. 2007 Feb; 1(2):148-56. PMID: 21136664.
      View in: PubMed
    150. Herlevsen M, Oxford G, Ptak C, Shabanowitz J, Hunt DF, Conaway M, Theodorescu D. A novel model to identify interaction partners of the PTEN tumor suppressor gene in human bladder cancer. Biochem Biophys Res Commun. 2007 Jan 12; 352(2):549-55. PMID: 17126809; PMCID: PMC1933505.
    151. Thomas CY, Theodorescu D. Collaboration of RON and epidermal growth factor receptor in human bladder carcinogenesis. J Urol. 2006 Nov; 176(5):1909-10. PMID: 17070208.
      View in: PubMed
    152. Thomas CY, Theodorescu D. Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas. World J Urol. 2006 Nov; 24(5):565-78. PMID: 17063322.
      View in: PubMed
    153. Fletcher SG, Mills SE, Smolkin ME, Theodorescu D. Case-matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer. Int J Radiat Oncol Biol Phys. 2006 Nov 15; 66(4):1092-9. PMID: 16965872.
      View in: PubMed
    154. Moon K, Stukenborg GJ, Keim J, Theodorescu D. Cancer incidence after localized therapy for prostate cancer. Cancer. 2006 Sep 01; 107(5):991-8. PMID: 16878323.
      View in: PubMed
    155. Moon K, Theodorescu D. Does saturation biopsy improve prostate cancer detection? Nat Clin Pract Urol. 2006 Sep; 3(9):468-9. PMID: 16964184.
      View in: PubMed
    156. Wu Y, McRoberts K, Berr SS, Frierson HF, Conaway M, Theodorescu D. Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia. Oncogene. 2007 Feb 01; 26(5):765-73. PMID: 16878152.
      View in: PubMed
    157. Wu Z, Conaway M, Gioeli D, Weber MJ, Theodorescu D. Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells. Prostate. 2006 Jul 01; 66(10):1114-23. PMID: 16637073.
      View in: PubMed
    158. Copp HL, Chin JL, Conaway M, Theodorescu D. Prospective evaluation of the prognostic relevance of molecular staging for urothelial carcinoma. Cancer. 2006 Jul 01; 107(1):60-6. PMID: 16691580.
      View in: PubMed
    159. Rinker-Schaeffer CW, O'Keefe JP, Welch DR, Theodorescu D. Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clin Cancer Res. 2006 Jul 01; 12(13):3882-9. PMID: 16818682; PMCID: PMC1525213.
    160. Rhee JJ, Lebeau S, Smolkin M, Theodorescu D. Radical cystectomy with ileal conduit diversion: early prospective evaluation of the impact of robotic assistance. BJU Int. 2006 Nov; 98(5):1059-63. PMID: 16796697.
      View in: PubMed
    161. Zürbig P, Renfrow MB, Schiffer E, Novak J, Walden M, Wittke S, Just I, Pelzing M, Neusüss C, Theodorescu D, Root KE, Ross MM, Mischak H. Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis. 2006 Jun; 27(11):2111-25. PMID: 16645980.
      View in: PubMed
    162. Keim JL, Theodorescu D. Robot-assisted radical cystectomy in the management of bladder cancer. ScientificWorldJournal. 2006 Mar 28; 6:2560-5. PMID: 17619731.
      View in: PubMed
    163. Miller NL, Theodorescu D. Status of robotic cystectomy in 2005. World J Urol. 2006 Jun; 24(2):180-7. PMID: 16557389.
      View in: PubMed
    164. Wu Z, Siadaty MS, Riddick G, Frierson HF, Lee JK, Golden W, Knuutila S, Hampton GM, El-Rifai W, Theodorescu D. A novel method for gene expression mapping of metastatic competence in human bladder cancer. Neoplasia. 2006 Mar; 8(3):181-9. PMID: 16611411; PMCID: PMC1578518.
    165. Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, Mischak H, Frierson HF. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol. 2006 Mar; 7(3):230-40. PMID: 16510332.
      View in: PubMed
    166. Smith SC, Oxford G, Wu Z, Nitz MD, Conaway M, Frierson HF, Hampton G, Theodorescu D. The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res. 2006 Feb 15; 66(4):1917-22. PMID: 16488989.
      View in: PubMed
    167. Titus B, Frierson HF, Conaway M, Ching K, Guise T, Chirgwin J, Hampton G, Theodorescu D. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res. 2005 Aug 15; 65(16):7320-7. PMID: 16103083.
      View in: PubMed
    168. Oxford G, Owens CR, Titus BJ, Foreman TL, Herlevsen MC, Smith SC, Theodorescu D. RalA and RalB: antagonistic relatives in cancer cell migration. Cancer Res. 2005 Aug 15; 65(16):7111-20. PMID: 16103060.
      View in: PubMed
    169. Theodorescu D, Fliser D, Wittke S, Mischak H, Krebs R, Walden M, Ross M, Eltze E, Bettendorf O, Wulfing C, Semjonow A. Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis. 2005 Jul; 26(14):2797-808. PMID: 15981297.
      View in: PubMed
    170. Miller N, Smolkin ME, Bissonette E, Theodorescu D. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy. Cancer. 2005 Jun 15; 103(12):2499-506. PMID: 15852361.
      View in: PubMed
    171. Copp H, Bissonette EA, Theodorescu D. Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer. Urology. 2005 Jun; 65(6):1146-51. PMID: 15922433.
      View in: PubMed
    172. Smith SC, Oxford G, Theodorescu D. The promise of gene-expression analysis in bladder cancer: a clinician's guide. BJU Int. 2005 Apr; 95(6):874-80. PMID: 15794801.
      View in: PubMed
    173. Fletcher SG, Theodorescu D. Surgery or radiation: what is the optimal management for locally advanced prostate cancer? Can J Urol. 2005 Feb; 12 Suppl 1:58-61; discussion 101-2. PMID: 15780168.
      View in: PubMed
    174. Koutrouvelis PG, Theodorescu D, Katz S, Lailas N, Hendricks F. Brachytherapy of prostate cancer after colectomy for colorectal cancer: pilot experience. J Urol. 2005 Jan; 173(1):82-5; discussion 85-6. PMID: 15592034.
      View in: PubMed
    175. Titus B, Schwartz MA, Theodorescu D. Rho proteins in cell migration and metastasis. Crit Rev Eukaryot Gene Expr. 2005; 15(2):103-14. PMID: 16022631.
      View in: PubMed
    176. Nicholson B, Gulding K, Conaway M, Wedge SR, Theodorescu D. Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach. Clin Cancer Res. 2004 Dec 15; 10(24):8728-34. PMID: 15623658.
      View in: PubMed
    177. Woolsey J, Bissonette E, Schneider BF, Theodorescu D. Prospective outcomes associated with migration from preoperative to intraoperative planned brachytherapy: a single center report. J Urol. 2004 Dec; 172(6 Pt 2):2528-31. PMID: 15538201.
      View in: PubMed
    178. Nicholson BE, Frierson HF, Conaway MR, Seraj JM, Harding MA, Hampton GM, Theodorescu D. Profiling the evolution of human metastatic bladder cancer. Cancer Res. 2004 Nov 01; 64(21):7813-21. PMID: 15520187.
      View in: PubMed
    179. Bradley EB, Bissonette EA, Theodorescu D. Determinants of long-term quality of life and voiding function of patients treated with radical prostatectomy or permanent brachytherapy for prostate cancer. BJU Int. 2004 Nov; 94(7):1003-9. PMID: 15541117.
      View in: PubMed
    180. Gildea JJ, Herlevsen M, Harding MA, Gulding KM, Moskaluk CA, Frierson HF, Theodorescu D. PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity. Oncogene. 2004 Sep 02; 23(40):6788-97. PMID: 15273733.
      View in: PubMed
    181. Miller NL, Theodorescu D. Health-related quality of life after prostate brachytherapy. BJU Int. 2004 Sep; 94(4):487-91. PMID: 15329098.
      View in: PubMed
    182. Theodorescu D, Sapinoso LM, Conaway MR, Oxford G, Hampton GM, Frierson HF. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res. 2004 Jun 01; 10(11):3800-6. PMID: 15173088.
      View in: PubMed
    183. Theodorescu D, Frierson HF. When is a negative lymph node really negative? Molecular tools for the detection of lymph node metastasis from urological cancer. Urol Oncol. 2004 May-Jun; 22(3):256-9. PMID: 15271328.
      View in: PubMed
    184. Bassignani M, Moore Y, Watson L, Theodorescu D. Pilot experience with real-time ultrasound guided percutaneous renal mass cryoablation. J Urol. 2004 Apr; 171(4):1620-3. PMID: 15017235.
      View in: PubMed
    185. Makhlouf AA, Krupski TL, Kunkle D, Theodorescu D. The effect of sampling more cores on the predictive accuracy of pathological grade and tumour distribution in the prostate biopsy. BJU Int. 2004 Feb; 93(3):271-4. PMID: 14764121.
      View in: PubMed
    186. Nicholson B, Theodorescu D. Angiogenesis and prostate cancer tumor growth. J Cell Biochem. 2004 Jan 01; 91(1):125-50. PMID: 14689586.
      View in: PubMed
    187. Ames CD, Frierson HF, Theodorescu D. Unusual case of recurrent low-grade invasive and endophytic squamous cell carcinoma of the penis. Scand J Urol Nephrol. 2004; 38(3):258-9. PMID: 15204384.
      View in: PubMed
    188. Theodorescu D. Cancer cryotherapy: evolution and biology. Rev Urol. 2004; 6 Suppl 4:S9-S19. PMID: 16985871; PMCID: PMC1472868.
    189. Horwitz EM, Uzzo RG, Miller N, Theodorescu D. Brachytherapy for prostate cancer: follow-up and management of treatment failures. Urol Clin North Am. 2003 Nov; 30(4):737-50, viii-ix. PMID: 14680311.
      View in: PubMed
    190. Oxford G, Theodorescu D. The role of Ras superfamily proteins in bladder cancer progression. J Urol. 2003 Nov; 170(5):1987-93. PMID: 14532839.
      View in: PubMed
    191. Woolsey J, Miller N, Theodorescu D. Permanent interstitial brachytherapy for prostate cancer: a current review. World J Urol. 2003 Sep; 21(4):209-19. PMID: 12920559.
      View in: PubMed
    192. Theodorescu D, Pollack A. Radiation for prostate cancer issue. World J Urol. 2003 Sep; 21(4):189. PMID: 12905007.
      View in: PubMed
    193. Theodorescu D. Phosphoinositide signaling in urological disease. J Urol. 2003 Jun; 169(6):2394-6. PMID: 12771804.
      View in: PubMed
    194. Hall JD, Bissonette EA, Boyd JC, Theodorescu D. Motivations and influences on the use of complementary medicine in patients with localized prostate cancer treated with curative intent: results of a pilot study. BJU Int. 2003 May; 91(7):603-7. PMID: 12699468.
      View in: PubMed
    195. Krupski T, Bissonette EA, Petroni GR, Theodorescu D. The impact of prostate volume following neoadjuvant androgen deprivation on quality of life and voiding symptoms in patients undergoing permanent prostate brachytherapy. Eur Urol. 2003 May; 43(5):467-72. PMID: 12705988.
      View in: PubMed
    196. Miller NL, Bissonette EA, Bahnson R, Wilson J, Theodorescu D. Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy. Cancer. 2003 Mar 01; 97(5):1203-10. PMID: 12599226.
      View in: PubMed
    197. Bigler D, Gulding KM, Dann R, Sheabar FZ, Conaway MR, Theodorescu D. Gene profiling and promoter reporter assays: novel tools for comparing the biological effects of botanical extracts on human prostate cancer cells and understanding their mechanisms of action. Oncogene. 2003 Feb 27; 22(8):1261-72. PMID: 12606954.
      View in: PubMed
    198. Hall JD, Boyd JC, Lippert MC, Theodorescu D. Why patients choose prostatectomy or brachytherapy for localized prostate cancer: results of a descriptive survey. Urology. 2003 Feb; 61(2):402-7. PMID: 12597956.
      View in: PubMed
    199. Oxford G, Theodorescu D. Ras superfamily monomeric G proteins in carcinoma cell motility. Cancer Lett. 2003 Jan 28; 189(2):117-28. PMID: 12490304.
      View in: PubMed
    200. Theodorescu D. Molecular pathogenesis of urothelial bladder cancer. Histol Histopathol. 2003 01; 18(1):259-74. PMID: 12507305.
      View in: PubMed
    201. Nicholson B, Theodorescu D. Molecular therapeutics in prostate cancer. Histol Histopathol. 2003 01; 18(1):275-98. PMID: 12507306.
      View in: PubMed
    202. Harding MA, Arden KC, Gildea JW, Gildea JJ, Perlman EJ, Viars C, Theodorescu D. Functional genomic comparison of lineage-related human bladder cancer cell lines with differing tumorigenic and metastatic potentials by spectral karyotyping, comparative genomic hybridization, and a novel method of positional expression profiling. Cancer Res. 2002 Dec 01; 62(23):6981-9. PMID: 12460916.
      View in: PubMed
    203. Valicenti RK, Bissonette EA, Chen C, Theodorescu D. Longitudinal comparison of sexual function after 3-dimensional conformal radiation therapy or prostate brachytherapy. J Urol. 2002 Dec; 168(6):2499-504; discussion 2504. PMID: 12441949.
      View in: PubMed
    204. Gildea JJ, Seraj MJ, Oxford G, Harding MA, Hampton GM, Moskaluk CA, Frierson HF, Conaway MR, Theodorescu D. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res. 2002 Nov 15; 62(22):6418-23. PMID: 12438227.
      View in: PubMed
    205. Coblentz TR, Theodorescu D. Morbidity of modified prophylactic inguinal lymphadenectomy for squamous cell carcinoma of the penis. J Urol. 2002 Oct; 168(4 Pt 1):1386-9. PMID: 12352399.
      View in: PubMed
    206. Makhlouf AA, Boyd JC, Chapman TN, Theodorescu D. Perioperative costs and charges of prostate brachytherapy and prostatectomy. Urology. 2002 Oct; 60(4):656-60. PMID: 12385928.
      View in: PubMed
    207. Smith EB, Frierson HF, Mills SE, Boyd JC, Theodorescu D. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading? Cancer. 2002 Apr 15; 94(8):2282-7. PMID: 12001128.
      View in: PubMed
    208. Gildea JJ, Harding MA, Seraj MJ, Gulding KM, Theodorescu D. The role of Ral A in epidermal growth factor receptor-regulated cell motility. Cancer Res. 2002 Feb 15; 62(4):982-5. PMID: 11861368.
      View in: PubMed
    209. Chesson JP, Theodorescu D. Adrenal tumor with caval extension--case report and review of the literature. Scand J Urol Nephrol. 2002 Feb; 36(1):71-3. PMID: 12002362.
      View in: PubMed
    210. Coblentz TR, Bissonette EA, Williams KR, Theodorescu D. Multimodality radiotherapy and androgen ablation in the treatment of clinically localized prostate cancer: early results in high risk patients. Prostate Cancer Prostatic Dis. 2002; 5(3):219-25. PMID: 12496985.
      View in: PubMed
    211. Karns LR, Kisielewski A, Gulding KM, Seraj JM, Theodorescu D. Manipulation of gene expression by an ecdysone-inducible gene switch in tumor xenografts. BMC Biotechnol. 2001; 1:11. PMID: 11782290; PMCID: PMC64497.
    212. Sheta EA, Trout H, Gildea JJ, Harding MA, Theodorescu D. Cell density mediated pericellular hypoxia leads to induction of HIF-1alpha via nitric oxide and Ras/MAP kinase mediated signaling pathways. Oncogene. 2001 Nov 15; 20(52):7624-34. PMID: 11753640.
      View in: PubMed
    213. Santen RJ, Petroni GR, Fisch MJ, Myers CE, Theodorescu D, Cohen RB. Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma. Cancer. 2001 Oct 15; 92(8):2095-101. PMID: 11596025.
      View in: PubMed
    214. Chen C, Frierson HF, Haggerty PF, Theodorescu D, Gregory CW, Dong JT. An 800-kb region of deletion at 13q14 in human prostate and other carcinomas. Genomics. 2001 Oct; 77(3):135-44. PMID: 11597138.
      View in: PubMed
    215. Theodorescu D, Older RA, Sorenson EJ. Metastatic melanoma presenting as an ileal conduit filling defect. J Urol. 2001 Oct; 166(4):1393-4. PMID: 11547088.
      View in: PubMed
    216. Smith E, Yoon J, Theodorescu D. Evaluation of urinary continence and voiding function: early results in men with neo-urethral modification of the Hautmann orthotopic neobladder. J Urol. 2001 Oct; 166(4):1346-9. PMID: 11547071.
      View in: PubMed
    217. Bissonette EA, Fulmer BR, Petroni GR, Moul JW, Theodorescu D. Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men. J Urol. 2001 Oct; 166(4):1328-31; discussion 1331-2. PMID: 11547067.
      View in: PubMed
    218. Seraj MJ, Thomas AR, Chin JL, Theodorescu D. Molecular determination of perivesical and lymph node metastasis after radical cystectomy for urothelial carcinoma of the bladder. Clin Cancer Res. 2001 Jun; 7(6):1516-22. PMID: 11410485.
      View in: PubMed
    219. Fulmer BR, Bissonette EA, Petroni GR, Theodorescu D. Prospective assessment of voiding and sexual function after treatment for localized prostate carcinoma: comparison of radical prostatectomy to hormonobrachytherapy with and without external beam radiotherapy. Cancer. 2001 Jun 01; 91(11):2046-55. PMID: 11391584.
      View in: PubMed
    220. Coblentz TR, Mills SE, Theodorescu D. Impact of second opinion pathology in the definitive management of patients with bladder carcinoma. Cancer. 2001 Apr 01; 91(7):1284-90. PMID: 11283928.
      View in: PubMed
    221. Krupski T, Harding MA, Herce ME, Gulding KM, Stoler MH, Theodorescu D. The role of vascular endothelial growth factor in the tissue specific in vivo growth of prostate cancer cells. Growth Factors. 2001; 18(4):287-302. PMID: 11519827.
      View in: PubMed
    222. Nicholson B, Schaefer G, Theodorescu D. Angiogenesis in prostate cancer: biology and therapeutic opportunities. Cancer Metastasis Rev. 2001; 20(3-4):297-319. PMID: 12085968.
      View in: PubMed
    223. Krupski T, Theodorescu D. Orthotopic neobladder following cystectomy: indications, management, and outcomes. J Wound Ostomy Continence Nurs. 2001 Jan; 28(1):37-46. PMID: 11174461.
      View in: PubMed
    224. Sheta EA, Harding MA, Conaway MR, Theodorescu D. Transformation dependent signalling pathways leading to transcriptional induction of vascular endothelial growth factor in prostate cancer. Prostate Cancer Prostatic Dis. 2000 Dec; 3(S1):S39. PMID: 12497147.
      View in: PubMed
    225. Theodorescu D, Gillenwater JY, Koutrouvelis PG. Prostatourethral-rectal fistula after prostate brachytherapy. Cancer. 2000 Nov 15; 89(10):2085-91. PMID: 11066049.
      View in: PubMed
    226. Gardner TA, Bissonette EA, Petroni GR, McClain R, Sokoloff MH, Theodorescu D. Surgical and postoperative factors affecting length of hospital stay after radical prostatectomy. Cancer. 2000 Jul 15; 89(2):424-30. PMID: 10918175.
      View in: PubMed
    227. Sheta EA, Harding MA, Conaway MR, Theodorescu D. Focal adhesion kinase, Rap1, and transcriptional induction of vascular endothelial growth factor. J Natl Cancer Inst. 2000 Jul 05; 92(13):1065-73. PMID: 10880549.
      View in: PubMed
    228. Gildea JJ, Harding MA, Gulding KM, Theodorescu D. Transmembrane motility assay of transiently transfected cells by fluorescent cell counting and luciferase measurement. Biotechniques. 2000 Jul; 29(1):81-6. PMID: 10907081.
      View in: PubMed
    229. Krupski T, Moskaluk C, Boyd JC, Theodorescu D. A prospective pilot evaluation of urinary and immunohistochemical markers as predictors of clinical stage of urothelial carcinoma of the bladder. BJU Int. 2000 Jun; 85(9):1027-32. PMID: 10848689.
      View in: PubMed
    230. Krupski T, Petroni GR, Bissonette EA, Theodorescu D. Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer. Urology. 2000 May; 55(5):736-42. PMID: 10792092.
      View in: PubMed
    231. Im DS, Heise CE, Harding MA, George SR, O'Dowd BF, Theodorescu D, Lynch KR. Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate. Mol Pharmacol. 2000 Apr; 57(4):753-9. PMID: 10727522.
      View in: PubMed
    232. Gildea JJ, Golden WL, Harding MA, Theodorescu D. Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer. Genes Chromosomes Cancer. 2000 Mar; 27(3):252-63. PMID: 10679914.
      View in: PubMed
    233. Seraj MJ, Harding MA, Gildea JJ, Welch DR, Theodorescu D. The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clin Exp Metastasis. 2000; 18(6):519-25. PMID: 11592309.
      View in: PubMed
    234. Lippert MC, McClain R, Boyd JC, Theodorescu D. Alternative medicine use in patients with localized prostate carcinoma treated with curative intent. Cancer. 1999 Dec 15; 86(12):2642-8. PMID: 10594859.
      View in: PubMed
    235. Krupski T, Petroni GR, Bissonette EA, Theodorescu D. Quality of life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer. Prostate Cancer Prostatic Dis. 1999 Nov; 2(S3):S32. PMID: 12496811.
      View in: PubMed
    236. Broder SR, Frierson HF, Theodorescu D. Unusual case of non-exophytic invasive penile squamous cell cancer arising from a chronic sinus tract. Scand J Urol Nephrol. 1999 Oct; 33(5):333-5. PMID: 10572999.
      View in: PubMed
    237. Theodorescu D, Frierson HF, Sikes RA. Molecular determination of surgical margins using fossa biopsies at radical prostatectomy. J Urol. 1999 May; 161(5):1442-8. PMID: 10210369.
      View in: PubMed
    238. Gray M, Petroni GR, Theodorescu D. Urinary function after radical prostatectomy: a comparison of the retropubic and perineal approaches. Urology. 1999 May; 53(5):881-90; discussion 890-1. PMID: 10223478.
      View in: PubMed
    239. Crane CH, Clark MM, Bissonette EA, Theodorescu D. Prospective evaluation of the effect of ionizing radiation on the bladder tumor-associated (BTA) urine test. Int J Radiat Oncol Biol Phys. 1999 Jan 01; 43(1):73-7. PMID: 9989516.
      View in: PubMed
    240. Theodorescu D, Laderoute KR, Calaoagan JM, Guilding KM. Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression. Int J Cancer. 1998 Dec 09; 78(6):775-82. PMID: 9833772.
      View in: PubMed
    241. Theodorescu D, Laderoute KR, Gulding KM. Epidermal growth factor receptor-regulated human bladder cancer motility is in part a phosphatidylinositol 3-kinase-mediated process. Cell Growth Differ. 1998 Nov; 9(11):919-28. PMID: 9831244.
      View in: PubMed
    242. Theodorescu D, Balcom A, Smith CR, McLorie GA, Churchill BM, Khoury AE. Urethral replacement with vascularized tunica vaginalis: defining the optimal form of use. J Urol. 1998 May; 159(5):1708-11. PMID: 9554398.
      View in: PubMed
    243. Theodorescu D, Lippert MC, Broder SR, Boyd JC. Early prostate-specific antigen failure following radical perineal versus retropubic prostatectomy: the importance of seminal vesicle excision. Urology. 1998 Feb; 51(2):277-82. PMID: 9495711.
      View in: PubMed
    244. Harding MA, Theodorescu D. Prognostic markers in localized prostate cancer: from microscopes to molecules. Cancer Metastasis Rev. 1998-1999; 17(4):429-37. PMID: 10453287.
      View in: PubMed
    245. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF. Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer. 1997 Dec 01; 80(11):2109-19. PMID: 9392333.
      View in: PubMed
    246. Lippert MC, Theodorescu D. The Hautmann neobladder with a chimney: a versatile modification. J Urol. 1997 Oct; 158(4):1510-2. PMID: 9302153.
      View in: PubMed
    247. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol. 1997 Jul; 158(1):131-7. PMID: 9186339.
      View in: PubMed
    248. Herrell SD, Trachtenberg J, Theodorescu D. Staging pelvic lymphadenectomy for localized carcinoma of the prostate: a comparison of 3 surgical techniques. J Urol. 1997 Apr; 157(4):1337-9. PMID: 9120934.
      View in: PubMed
    249. Lajvardi A, Theodorescu D, Older RA. A müllerian duct cyst presenting as a large complex pelvic mass. J Urol. 1997 Mar; 157(3):958. PMID: 9072616.
      View in: PubMed
    250. Frierson HF, Theodorescu D, Mills SE, Hanigan MH. gamma-Glutamyl transpeptidase in normal and neoplastic prostate glands. Mod Pathol. 1997 Jan; 10(1):1-6. PMID: 9021720.
      View in: PubMed
    251. Theodorescu D, Russo P, Zhang ZF, Morash C, Fair WR. Outcomes of initial surveillance of invasive squamous cell carcinoma of the penis and negative nodes. J Urol. 1996 May; 155(5):1626-31. PMID: 8627839.
      View in: PubMed
    252. Theodorescu D. Prostate cancer--our patients' questions. J Urol. 1996 May; 155(5):1661-2. PMID: 8627848.
      View in: PubMed
    253. Theodorescu D. Commentary on genetic prognostic markers for transitional cell carcinoma of the bladder: from microscopes to molecules. J Urol. 1996 Jan; 155(1):2. PMID: 7490833.
      View in: PubMed
    254. Huang F, Newman E, Theodorescu D, Kerbel RS, Friedman E. Transforming growth factor beta 1 (TGF beta 1) is an autocrine positive regulator of colon carcinoma U9 cells in vivo as shown by transfection of a TGF beta 1 antisense expression plasmid. Cell Growth Differ. 1995 Dec; 6(12):1635-42. PMID: 9019169.
      View in: PubMed
    255. Theodorescu D, Connors KM, Groce A, Hoffman RM, Kerbel RS. Lack of influence of c-Ha-ras expression on the drug sensitivity of human bladder cancer histocultured in three-dimensions. Anticancer Res. 1993 Jul-Aug; 13(4):941-6. PMID: 8352563.
      View in: PubMed
    256. Schuh AC, Theodorescu D, Shalaby F, Breitman ML. Altered growth and spontaneous transformation of cells cultured from v-jun transgenic mice recapitulate wound-induced multistage tumorigenesis. Cell Growth Differ. 1993 Mar; 4(3):177-84. PMID: 8466856.
      View in: PubMed
    257. Theodorescu D, Sheehan C, Kerbel RS. TGF-beta gene expression depends on tissue architecture. In Vitro Cell Dev Biol. 1993 Feb; 29A(2):105-8. PMID: 8473265.
      View in: PubMed
    258. Theodorescu D, Binnington AG, Connolly JG. The intestinoprostatic capsule anastomosis: functional and anatomic results in a canine model. Can J Surg. 1992 Apr; 35(2):169-72. PMID: 1562927.
      View in: PubMed
    259. Wu SP, Theodorescu D, Kerbel RS, Willson JK, Mulder KM, Humphrey LE, Brattain MG. TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J Cell Biol. 1992 Jan; 116(1):187-96. PMID: 1730743; PMCID: PMC2289262.
    260. Fu XY, Theodorescu D, Kerbel RS, Hoffman RM. Extensive multi-organ metastasis following orthotopic onplantation of histologically-intact human bladder carcinoma tissue in nude mice. Int J Cancer. 1991 Dec 02; 49(6):938-9. PMID: 1959996.
      View in: PubMed
    261. Kerbel RS, Cornil I, Theodorescu D. Importance of orthotopic transplantation procedures in assessing the effects of transfected genes on human tumor growth and metastasis. Cancer Metastasis Rev. 1991 Oct; 10(3):201-15. PMID: 1764765.
      View in: PubMed
    262. Theodorescu D, Caltabiano M, Greig R, Rieman D, Kerbel RS. Reduction of TGF-beta activity abrogates growth promoting tumor cell-cell interactions in vivo. J Cell Physiol. 1991 Sep; 148(3):380-90. PMID: 1655815.
      View in: PubMed
    263. Theodorescu D, Cornil I, Sheehan C, Man MS, Kerbel RS. Ha-ras induction of the invasive phenotype results in up-regulation of epidermal growth factor receptors and altered responsiveness to epidermal growth factor in human papillary transitional cell carcinoma cells. Cancer Res. 1991 Aug 15; 51(16):4486-91. PMID: 1868471.
      View in: PubMed
    264. Cornil I, Theodorescu D, Man S, Herlyn M, Jambrosic J, Kerbel RS. Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci U S A. 1991 Jul 15; 88(14):6028-32. PMID: 2068080; PMCID: PMC52015.
    265. Cornil I, Theodorescu D, Kerbel RS, Poupon MF. [Metastatic dissemination of cancer cells]. Pathol Biol (Paris). 1991 Apr; 39(4):300-7. PMID: 1712092.
      View in: PubMed
    266. Theodorescu D, Cornil I, Sheehan C, Man S, Kerbel RS. Dominance of metastatically competent cells in primary murine breast neoplasms is necessary for distant metastatic spread. Int J Cancer. 1991 Jan 02; 47(1):118-23. PMID: 1985866.
      View in: PubMed
    267. Theodorescu D, Bergsma D, Man MS, Elshourbagy N, Sheehan C, Rieman D, Kerbel RS. Cloning and overexpression of TGF-beta 1 cDNA in a mammary adenocarcinoma: in vitro and in vivo effects. Growth Factors. 1991; 5(4):305-16. PMID: 1777239.
      View in: PubMed
    268. Theodorescu D, Witchell S, Connolly J. Chronic adult renal vein thrombosis: two unusual cases and a review of the literature. Int Urol Nephrol. 1991; 23(5):429-35. PMID: 1938241.
      View in: PubMed
    269. Theodorescu D, Cornil I, Fernandez BJ, Kerbel RS. Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma. Proc Natl Acad Sci U S A. 1990 Nov; 87(22):9047-51. PMID: 2247480; PMCID: PMC55098.
    270. Adams C, Theodorescu D, Murphy EG, Shandling B. Thymectomy in juvenile myasthenia gravis. J Child Neurol. 1990 Jul; 5(3):215-8. PMID: 2398237.
      View in: PubMed
    271. Blair GK, Filler RM, Theodorescu D. Neonatal pharyngoesophageal perforation mimicking esophageal atresia: clues to diagnosis. J Pediatr Surg. 1987 Aug; 22(8):770-4. PMID: 3656031.
      View in: PubMed
    272. Theodorescu D, Munteanu F, Munteanu L. [Peritoneal pseudomyxoma]. Chirurgia (Bucur). 1972 Oct; 21(10):899-904. PMID: 4670226.
      View in: PubMed
    273. THEODORESCU D. [Physiopathology of the opening at the anastomosis following resection of the stomach]. Concours Med. 1958 Jun 21; 80(25):3049-52 passim. PMID: 13547669.
      View in: PubMed
    Theodorescu's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)